Creo Medical Group plc
("Creo" the "Company" or the
"Group")
Award of
Shares under Share Incentive Plan, Director Dealings, Issue of
Equity and TVR
Creo Medical Group
plc (AIM: CREO), a medical device company focused on the
emerging field of minimally invasive surgical endoscopy for
pre-cancer and cancer patients, implemented an HMRC approved Share
Incentive Plan ("SIP") during 2020 which is available to all of the
Company's UK based employees, including Directors.
Under the SIP,
shares are acquired in four ways:
· Partnership Shares where an employee can
spend up to a £1,800 or 10% of their pre-tax income, whichever is
the lower;
· Matching Shares, where Creo can give up to
two free Matching Shares for each Partnership Share bought.
The plan requires employees to remain in employment for three years
to benefit from the Matching Shares;
· Free Shares, where Creo can give up to
£3,600 of free shares in any tax year; and
· Dividend Shares where additional shares can
be bought with any dividends paid.
The Company has
been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the
independent trustee of the SIP, acquired, in accordance with the
SIP's rules and on behalf of SIP participants, 248,132 ordinary
shares in the Company ("Ordinary Shares"), at a price of £0.191 per
Ordinary Share on 16 January 2025 to meet its obligations under the
SIP. Under the terms of the SIP, the Company is required to
issue to the SIP, two Ordinary Shares in the Company for each
Partnership Share purchased (being 496,264 Ordinary Shares in
total). Fiduchi holds 171,924 unallocated shares within the
SIP (being shares previously allocated to employees who ceased
employment before the shares had vested) which can be utilised to
part satisfy the Company's obligation. Accordingly, 324,340 new
Ordinary Shares are required to be issued by the Company to be held
by Fiduchi as trustee of the SIP.
Craig Gulliford,
Richard Rees and Christopher Hancock, executive directors of the
Company (the "Participating Directors") have received Partnership
Shares at a price of £0.191 per share and Matching Shares at a
price of £0.001 per share in accordance with terms of the SIP (the
"Transaction"). Following this the Participating Directors'
shareholdings in the Company are as set out in the table
below:
|
Director
|
Total number of Ordinary Shares purchased or
awarded under SIP
|
Total number of Ordinary Shares held post
Transaction
|
|
Craig Gulliford,
CEO
|
14,136
|
1,666,9071
|
|
Richard Rees,
CFO
|
14,136
|
3,050,6762
|
|
Christopher
Hancock, CTO
|
14,136
|
4,838,793
|
Accordingly, the
Company announces that it has made an application for 324,340 new
Ordinary Shares to be admitted to trading on AIM. It is
expected that admission will take place on 28 January 2025.
Following the allotment and issue, the Company's issued share
capital consists of 412,473,319 Ordinary Shares. The Company
does not hold any shares in Treasury. As such the total number of
shares in issue with voting rights is 412,473,319.
Total Voting Rights (TVR)
The above figure
of 412,473,319 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure Guidance
and Transparency Rules.
The notifications
below, made in accordance with the requirements of the Market Abuse
Regulation, provide further detail in relation to the award of the
SIP Shares to the Participating Directors.
Notes:
1 Includes shares held by Mr Gulliford's
wife.
2 Includes shares held by Mr Rees's
wife.
For
further information please contact:
|
Creo Medical Group
plc
|
www.creomedical.com
|
|
Richard Craven, Company Secretary
|
Via Walbrook PR
|
|
|
|
|
Cavendish Capital
Markets Limited
(Nominated Adviser
and Joint Broker)
|
+44 (0)20 7220 0500
|
|
Stephen Keys / Camilla Hume / George Lawson
(NOMAD)
|
|
|
Michael Johnson (Sales)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan Brown
|
+44 (0)20
7260 1000
|
|
|
|
|
Walbrook PR
Ltd
|
Tel: +44 (0)20 7933 8780
or creo@walbrookpr.com
|
|
Paul McManus / Alice Woodings
Phillip Marriage
|
Mob: +44 (0)7980 541 893 /
+44 (0)7407 804 654
Mob: +44 (0)7867 984
082
|
|
|
| |
About Creo
Medical
Creo is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes
through the development and commercialisation of a suite of
electrosurgical medical devices, each enabled by CROMA, powered by
Kamaptive. The Group has developed the CROMA powered by Kamaptive
full-spectrum adaptive technology to optimise surgical capability
and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically
adapt to patient tissue during procedures such as resection,
dissection, coagulation, and ablation of tissue. Kamaptive
technology provides clinicians with increased flexibility,
precision and controlled surgical solutions. CROMA currently
delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for
controlled coagulation and ablation via a single accessory port.
This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with
flexible, accurate and controlled clinical solutions. The Directors
believe the Company's technology can impact the landscape of
surgery and endoscopy by providing a safer, less invasive and more
cost-efficient option for procedures.
For more information, please refer to the website
www.creomedical.com
|
1.
Details of PDMR
|
|
a)
|
Name
|
Craig Gulliford
|
|
b)
|
Position / status
|
CEO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.191
|
4,712
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2025-01-16 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Craig Gulliford
|
|
b)
|
Position / status
|
CEO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Award of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.001
|
9,424
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2025-01-20 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Richard Rees
|
|
b)
|
Position / status
|
CFO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.191
|
4,712
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2025-01-16 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Richard Rees
|
|
b)
|
Position / status
|
CFO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Award of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.001
|
9,424
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2025-01-20 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Christopher Hancock
|
|
b)
|
Position / status
|
CTO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.191
|
4,712
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2025-01-20 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Christopher Hancock
|
|
b)
|
Position / status
|
CTO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Award of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.001
|
9,424
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2025-01-20 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|